10.2 Sepsis, Septic Shock, and Systemic Complications

Sepsis, Septic Shock, and Systemic Complications

Sepsis represents one of the foremost causes of critical illness, in-hospital mortality, and healthcare expenditure worldwide. The management of sepsis and septic shock sits at the intersection of critical care pharmacology, fluid hemodynamics, diagnostic microbiology, and antimicrobial stewardship. Success demands rapid recognition, urgent physiological stabilization, and precise, biomarker-guided antimicrobial optimization.

---

Surviving Sepsis Campaign Guidelines and the Sepsis-3 Framework

Sepsis-3 Consensus Definitions

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) replaced historical criteria based on the Systemic Inflammatory Response Syndrome (SIRS), which lacked specificity and failed to distinguish uncomplicated infection from true life-threatening host dysregulation.

                             Sepsis-3 Diagnostic Cascade

          ┌────────────────────────────────────────────────────────┐
          │             Suspected or Documented Infection          │
          └───────────────────────────┬────────────────────────────┘
                                      │
                                      ▼
                  Acute Change in Total SOFA Score ≥ 2 Points
               (Reflects Life-Threatening Organ Dysfunction)
                                      │
                                      ▼
                                  = SEPSIS
                                      │
                ┌─────────────────────┴─────────────────────┐
                │                                           │
                ▼                                           ▼
       Adequate Fluid Resuscitation                Fluid Resuscitation Complete
       Restores MAP ≥ 65 mmHg                      Persistent Hypotension:
       and Lactate Clears                          - Requires Vasopressor for MAP ≥ 65 mmHg
                │                                    AND
                ▼                                  - Serum Lactate > 2 mmol/L (18 mg/dL)
         SEPSIS RESOLVING                                   │
                                                            ▼
                                                     = SEPTIC SHOCK
                                               (In-hospital mortality > 40%)

• Sepsis: Defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Clinically, organ dysfunction is operationalized as an acute increase in the total Sequential Organ Failure Assessment (SOFA) score of ≥ 2 points attributable to the infectious insult. (Baseline SOFA is assumed to be 0 unless pre-existing organ dysfunction is documented). An acute rise of SOFA ≥ 2 confers an in-hospital mortality rate exceeding 10%.
• Quick SOFA (qSOFA): Consists of three bedside clinical criteria:
  1. Respiratory rate ≥ 22 breaths/min.
  2. Altered mental status (Glasgow Coma Scale score < 15).
  3. Systolic blood pressure ≤ 100 mmHg. Guideline Caveat: While originally proposed as an early bedside tool, the Surviving Sepsis Campaign (SSC) 2021 guidelines recommend against using qSOFA as a single screening tool for sepsis or septic shock due to low sensitivity (missing up to 40% of septic patients). More comprehensive screening tools such as the National Early Warning Score (NEWS), Modified Early Warning Score (MEWS), or systemic inflammatory screening are strongly preferred.
• Septic Shock: Defined as a subset of sepsis in which underlying circulatory and cellular/metabolic abnormalities are profound enough to substantially increase mortality. Clinically identified by the requirement for:
  1. Vasopressors to maintain a Mean Arterial Pressure (MAP) ≥ 65 mmHg, AND
  2. A serum lactate level > 2 mmol/L (18 mg/dL) despite adequate fluid resuscitation. In-hospital mortality among patients meeting septic shock criteria exceeds 40%.

Sequential Organ Failure Assessment (SOFA) Scoring Components

The SOFA score evaluates six distinct physiologic organ systems (graded 0 to 4 points each):

1. Respiration: PaO₂ / FiO₂ ratio (< 400: 1 pt; < 300: 2 pts; < 200 with mechanical ventilation: 3 pts; < 100 with mechanical ventilation: 4 pts).
2. Coagulation: Platelet count (< 150 × 10³/μL: 1 pt; < 100: 2 pts; < 50: 3 pts; < 20: 4 pts).
3. Liver: Serum total bilirubin (1.2–1.9 mg/dL: 1 pt; 2.0–5.9: 2 pts; 6.0–11.9: 3 pts; ≥ 12.0: 4 pts).
4. Cardiovascular: Mean arterial pressure or required inotropic/vasopressor support (MAP < 70 mmHg: 1 pt; dopamine ≤ 5 or dobutamine any dose: 2 pts; dopamine > 5 or norepinephrine ≤ 0.1 mcg/kg/min: 3 pts; dopamine > 15 or norepinephrine > 0.1 mcg/kg/min: 4 pts).
5. Central Nervous System: Glasgow Coma Scale score (13–14: 1 pt; 10–12: 2 pts; 6–9: 3 pts; < 6: 4 pts).
6. Renal: Serum creatinine or daily urine output (creatinine 1.2–1.9 mg/dL: 1 pt; 2.0–3.4: 2 pts; 3.5–4.9 or urine < 500 mL/day: 3 pts; ≥ 5.0 or urine < 200 mL/day: 4 pts).

---

The Hour-1 Resuscitation Bundle and Hemodynamic Optimization

The Surviving Sepsis Campaign's "Hour-1 Bundle" encapsulates core resuscitation interventions that must be initiated immediately upon identification of sepsis or septic shock:

                          Surviving Sepsis Campaign Hour-1 Bundle

  1. MEASURE LACTATE ────────► Remeasure within 2-4 hours if initial lactate > 2 mmol/L
                                to assess clearance kinetics and tissue reperfusion.

  2. OBTAIN BLOOD CULTURES ──► At least 2 sets (aerobic + anaerobic) prior to antimicrobials;
                                do not delay antibiotics > 45 minutes if cultures difficult.

  3. ADMINISTER ANTIMICROBIALS► Broad-spectrum IV therapy within 1 HOUR for shock or high suspicion;
                                within 3 hours if sepsis possible but shock absent.

  4. RAPID IV FLUIDS ────────► Administer ≥ 30 mL/kg IV balanced crystalloid within 3 hours
                                for hypotension (MAP < 65 mmHg) or initial lactate ≥ 4 mmol/L.

  5. INITIATE VASOPRESSORS ──► Start during or after fluid loading if MAP remains < 65 mmHg;
                                First-line: Norepinephrine (titrate to MAP ≥ 65 mmHg).
                                Second-line: Vasopressin (fixed 0.03 units/min).

1. Fluid Resuscitation: Crystalloid Selection and Volume

• Target Volume: For patients with sepsis-induced hypoperfusion (defined as mean arterial pressure < 65 mmHg or initial serum lactate ≥ 4 mmol/L [36 mg/dL]), guidelines strongly recommend administering at least 30 mL/kg of intravenous crystalloid fluid within the first 3 hours of presentation.
  • Actual body weight should be utilized for initial calculations, though clinical discretion is advised in severe morbid obesity.
• Fluid Selection:
  • Balanced Crystalloids (Lactated Ringer's or Plasma-Lyte) are preferred over 0.9% Normal Saline. The large randomized SMART and SALT-ED clinical trials demonstrated that resuscitation with balanced crystalloids results in lower rates of major adverse kidney events (MAKE30; composite of death, new renal replacement therapy, or persistent renal dysfunction) compared to 0.9% saline. Infusion of large volumes of normal saline (0.9% NaCl, chloride concentration 154 mEq/L) induces hyperchloremic metabolic acidosis, renal afferent arteriolar vasoconstriction, and decreases glomerular filtration rate.
  • Albumin: For patients who have received large volumes of crystalloids (e.g., > 30–60 mL/kg) and remain hemodynamically unstable, the addition of 5% or 20% human albumin is suggested to maintain oncotic pressure and reduce total positive fluid balance.
  • Contraindicated Fluids: Hydroxyethyl starches (HES) and gelatins are strictly contraindicated due to clear evidence of increased acute kidney injury, need for renal replacement therapy, and increased mortality.
• Assessing Fluid Responsiveness: Following the initial 30 mL/kg bolus, indiscriminate fluid administration leads to interstitial edema, worsening pulmonary gas exchange, intra-abdominal hypertension, and increased mortality. Clinicians must assess fluid responsiveness using dynamic measures (e.g., passive leg raise test with real-time stroke volume measurement, stroke volume variation [SVV], pulse pressure variation [PPV] on mechanical ventilation, or dynamic bedside echocardiography of inferior vena cava collapsibility) rather than static parameters like central venous pressure (CVP).

2. Vasopressor Therapy and Hemodynamic Targets

Vasopressors are indicated when fluid administration fails to restore an adequate perfusion pressure, or initiated concurrently during fluid loading in severe shock to avert prolonged organ hypoperfusion:

• Hemodynamic Target: Titrate vasopressors to maintain a Mean Arterial Pressure (MAP) target of ≥ 65 mmHg. Targeting higher MAP goals (e.g., 75–85 mmHg) does not improve organ perfusion or renal outcomes, while significantly increasing the incidence of cardiac arrhythmias, excessive myocardial oxygen consumption, and vasopressor-induced peripheral ischemia (OVATION trial).
• Vasopressor Sequencing:
  1. First-Line: Norepinephrine:
     • Potent alpha-1-adrenergic receptor agonist causing intense peripheral vasoconstriction, combined with modest beta-1-inotropic activity that preserves cardiac stroke volume.
     • Demonstrates superior survival and a 50% lower rate of tachyarrhythmias compared to dopamine (SOAP II trial). Titrated from 0.02 to 1.0+ mcg/kg/min.
     • Peripheral IV administration in a well-placed vein (proximal to the antecubital fossa) is safe for short durations (< 24 hours) while central venous access is secured.
  2. Second-Line: Vasopressin (Arginine Vasopressin, AVP):
     • Acts on vascular V1 receptors on vascular smooth muscle, stimulating phospholipase C and vasoconstriction through pathways independent of adrenergic receptors.
     • Endogenous vasopressin stores become depleted within hours of septic shock onset (relative vasopressin deficiency).
     • Fixed, non-titrated dose of 0.03 units/min added to norepinephrine when norepinephrine requirements reach 0.25 mcg/kg/min or higher.
     • Provides a profound "norepinephrine-sparing" effect, raises MAP, and reduces arrhythmogenic adrenergic toxicity (VASST trial).
     • Rule: Vasopressin is never used as a monotherapy or titrated up and down in septic shock; doses > 0.03–0.04 units/min cause severe coronary and mesenteric vasoconstriction.
  3. Third-Line: Epinephrine:
     • Potent dual alpha-1 and beta-1 (with minor beta-2) adrenergic agonist. Added to norepinephrine plus vasopressin when MAP remains < 65 mmHg.
     • May transiently elevate serum lactate levels due to beta-2-mediated stimulation of skeletal muscle aerobic glycolysis (type B hyperlactatemia), which should not be confused with worsening tissue hypoperfusion.
  4. Inotropic Agent: Dobutamine:
     • Selective beta-1-agonist (with mild beta-2 vasodilation). Indicated when there is evidence of persistent tissue hypoperfusion (elevated lactate, low central venous oxygen saturation [ScvO₂ < 70%]) despite adequate intravascular volume and adequate MAP, or in the presence of documented myocardial dysfunction (septic cardiomyopathy).
     • Dosed at 2.5 to 20 mcg/kg/min.
  5. Agents to Avoid or Restrict:
     • Dopamine: Associated with substantial tachyarrhythmias and higher mortality; restricted to rare patients with low cardiac output and concurrent absolute or relative bradycardia.
     • Phenylephrine: Pure alpha-1-agonist that increases afterload without inotropic support; reduces stroke volume and cardiac output. Avoided except when norepinephrine produces refractory tachyarrhythmias or when cardiac output is known to be supranormal.

---

Antimicrobial Stewardship in Sepsis and Septic Shock

Timing and Empiric Selection

• The 1-Hour Benchmark: For adult patients with septic shock or where sepsis is highly suspected or definite, intravenous antimicrobials must be administered within 1 hour of recognition.
  • Retrospective and prospective studies show that in septic shock, each hour of delay in administering appropriate antimicrobials is associated with a 4% to 8% linear increase in mortality.
• The 3-Hour Benchmark (Diagnostic Workup Window): For patients with possible sepsis without shock, if the diagnosis of infection is unconfirmed, guidelines permit a rapid, structured diagnostic evaluation (up to 3 hours from recognition) to establish whether infection is present before committing to broad-spectrum antimicrobials.
• Empiric Spectrum: The empiric regimen must provide broad bactericidal coverage directed against all probable pathogens based on the suspected primary site of infection (pulmonary, abdominal, urinary, central line, skin), local hospital antibiograms, and patient-specific risk factors (prior MDRO colonization, recent antibiotic exposure, immunosuppression, structural lung disease).

Combination Gram-Negative Therapy in Shock

• In patients with septic shock or a high probability of resistant pathogens (e.g., known colonization with P. aeruginosa, ESBL, or CRE):
  • Guidelines recommend empiric combination therapy with two antimicrobials from different classes providing Gram-negative coverage (e.g., an antipseudomonal beta-lactam plus an antipseudomonal fluoroquinolone [ciprofloxacin/levofloxacin] or aminoglycoside [amikacin/tobramycin]).
  • Rationale: Ensures at least one active agent is delivered empirically when local resistance is high.
  • De-escalation: Once pathogen identity and antimicrobial susceptibility testing (AST) results are known, or if clinical improvement occurs within 48 to 72 hours, routine discontinuation of the second Gram-negative agent (de-escalation to monotherapy) is mandatory.

Biomarkers and Duration of Antimicrobial Therapy

• Short-Course Antimicrobial Therapy: Clinical trials consistently demonstrate that short-course antimicrobial therapy (5 to 7 days) is as effective as traditional 10- to 14-day courses for most infections causing sepsis (including community-acquired pneumonia, pyelonephritis, uncomplicated bacteremia, and intra-abdominal infections with adequate source control).
• Procalcitonin-Guided Discontinuation:
  • Procalcitonin is an inflammatory peptide precursor synthesized by parenchymal cells in response to bacterial endotoxin and pro-inflammatory cytokines (IL-1β, TNF-α), while being inhibited by viral interferon-γ.
  • Procalcitonin levels should not be used to decide whether to initiate antimicrobials in sepsis.
  • Procalcitonin algorithms are highly valuable for guiding antimicrobial discontinuation: antimicrobials can be safely discontinued when procalcitonin drops by ≥ 80% from peak or reaches an absolute level of < 0.5 ng/mL (or < 0.25 ng/mL) in a clinically stabilized patient with completed source control.

---

Corticosteroids in Septic Shock

Septic shock induces dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, downregulation of peripheral vascular adrenergic receptors, and excessive endogenous nitric oxide production, a constellation termed Critical Illness-Related Corticosteroid Insufficiency (CIRCI).

                         Corticosteroid Use in Septic Shock

            ┌────────────────────────────────────────────────────────┐
            │      Patient with Documented Septic Shock in ICU       │
            └───────────────────────────┬────────────────────────────┘
                                        │
                     Are ongoing vasopressors required
                     (e.g., Norepinephrine ≥ 0.25 mcg/kg/min)
                     after ≥ 4 hours of adequate fluid resuscitation?
                                        │
                       ┌────────────────┴────────────────┐
                       ▼ YES                             ▼ NO
     ┌───────────────────────────────────┐     ┌───────────────────────────────────┐
     │  INITIATE INTRAVENOUS STEROIDS    │     │       DO NOT ADMINISTER           │
     │  - Hydrocortisone 200 mg/day      │     │       SYSTEMIC STEROIDS           │
     │    (50 mg IV q6h OR               │     │                                   │
     │     200 mg/day continuous IV)     │     │ Steroids provide NO benefit and   │
     │  - Optional: Fludrocortisone      │     │ increase superinfections,         │
     │    50 mcg PO daily                │     │ hyperglycemia, and neuromuscular  │
     │                                   │     │ weakness in responsive shock.     │
     │ Taper promptly once vasopressors  │     └───────────────────────────────────┘
     │ have been discontinued.           │
     └───────────────────────────────────┘

Clinical Trial Evidence and Guideline Recommendations

• Indications: Surviving Sepsis Campaign guidelines recommend intravenous corticosteroids ONLY in adult patients with septic shock who have ongoing vasopressor requirements despite adequate fluid resuscitation.
  • Typically defined as a requirement for norepinephrine or epinephrine at a dose ≥ 0.25 mcg/kg/min for at least 4 hours to maintain MAP ≥ 65 mmHg.
  • Corticosteroids are contraindicated in sepsis without shock or in mild shock that rapidly resolves with initial fluids.
• Regimen and Administration:
  • Intravenous Hydrocortisone 200 mg per day, administered as either:
    • 50 mg IV every 6 hours, OR
    • 200 mg/day continuous intravenous infusion (preferred in patients with brittle glycemic control, as continuous infusion produces less glucose variability).
  • Fludrocortisone: Oral fludrocortisone (50 mcg once daily via nasogastric tube) was included in the French APROCCHSS trial, which demonstrated a statistically significant 90-day mortality benefit (43.0% vs 49.1%, p=0.03) when combined with hydrocortisone. The massive ADRENAL trial (which tested hydrocortisone alone without fludrocortisone) did not show a 90-day mortality reduction, but demonstrated significantly accelerated shock reversal (median 3 vs 4 days), shorter time on mechanical ventilation, and lower transfusion requirements. Fludrocortisone is optional; hydrocortisone at 200 mg/day possesses significant intrinsic mineralocorticoid activity.
• Key Rules for Corticosteroid Administration:
  • ACTH stimulation testing (cosyntropin test) is not recommended to select patients; clinical vasopressor dependency is the sole trigger.
  • High-dose corticosteroids (> 400 mg/day hydrocortisone equivalent) or pulse methylprednisolone must never be used in sepsis, as clinical trials show higher mortality and secondary opportunistic infections.
  • Hydrocortisone should be tapered once vasopressors have been successfully weaned.

---

Vector-Borne and Zoonotic Complex Infections

Systemic infectious syndromes caused by arthropod vectors (ticks, fleas, mites) and zoonotic reservoirs can present with fulminant multiorgan failure, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and shock, mimicking conventional bacterial sepsis.

1. Lyme Disease (Borrelia burgdorferi)

• Vector & Transmission: Transmitted by the bite of infected Ixodes scapularis (deer tick, blacklegged tick) in the Northeast and Upper Midwest, and Ixodes pacificus on the Pacific Coast. Tick attachment must generally exceed 24 to 36 hours for spirochete transmission to occur.
• Clinical Manifestations:
  • Early Localized Disease (Days 3–30): Classic Erythema Migrans (EM)—an expanding erythematous annular lesion, often with central clearing ("bull's-eye" appearance), measuring ≥ 5 cm in diameter. Accompanied by flu-like constitutional symptoms (fever, malaise, myalgias, arthralgias, headache). Diagnosis is purely clinical; serology is insensitive (< 40%) during early localized disease and should not delay treatment.
  • Early Disseminated Disease (Weeks to Months): Hematogenous dissemination resulting in multiple secondary annular EM lesions, cranial neuropathies (facial nerve [Cranial Nerve VII] palsy, frequently bilateral), lymphocytic meningitis, and Lyme carditis (manifesting as fluctuating atrioventricular [AV] nodal conduction block: first-, second-, or third-degree heart block, or myocarditis).
  • Late Disease (Months to Years): Recurrent or chronic monoarticular or asymmetric oligoarticular arthritis, most commonly involving the knee, with large synovial effusions; rare late encephalopathy or polyneuropathy.
• Laboratory Diagnosis: Two-tiered testing algorithm:
  1. First Tier: Sensitive enzyme immunoassay (EIA) or immunofluorescence assay (IFA).
  2. Second Tier: Standard Western immunoblot (IgM and IgG if symptoms < 30 days; IgG only if symptoms > 30 days) OR a second distinct FDA-cleared EIA (modified two-tier algorithm).
• Pharmacotherapeutic Management:
  • Early Localized EM, Isolated Cranial Nerve VII Palsy, or Mild Carditis (1st degree AV block with PR interval < 300 ms):
    • Doxycycline 100 mg PO twice daily for 10 to 14 days (preferred due to co-treatment of unrecognized Anaplasma).
    • Alternatives: Amoxicillin 500 mg PO three times daily for 14 days; Cefuroxime axetil 500 mg PO twice daily for 14 days.
  • Severe Lyme Neuroborreliosis (Meningitis, radiculoneuropathy) or Severe Lyme Carditis (Symptomatic, 2nd or 3rd degree AV block, or PR interval ≥ 300 ms):
    • Intravenous Ceftriaxone 2 g IV once daily for 14 to 21 days (patients with carditis can be stepped down to oral doxycycline once AV block resolves to complete 14–21 total days).
    • Alternative IV agents: Cefotaxime 2 g IV q8h or aqueous Penicillin G 18–24 million units/day continuous or divided q4h.
  • Lyme Arthritis: Oral Doxycycline 100 mg PO BID for 28 days (if refractory, retreatment with IV ceftriaxone 2 g daily for 14–28 days is indicated).

2. Anaplasmosis and Ehrlichiosis

• Etiology & Vectors:
  • Human Granulocytic Anaplasmosis (HGA): Caused by Anaplasma phagocytophilum, transmitted by Ixodes scapularis (same vector as Lyme and Babesia; co-infections are common).
  • Human Monocytic Ehrlichiosis (HME): Caused by Ehrlichia chaffeensis, transmitted by Amblyomma americanum (Lone Star tick), endemic in the Southeast and South-Central United States.
• Pathophysiology & Cellular Tropism:
  • A. phagocytophilum infects host granulocytes (neutrophils); E. chaffeensis infects monocytes and macrophages.
  • Both replicate within membrane-bound cytoplasmic vacuoles, forming diagnostic microcolonies termed morulae.
• Clinical Presentation: Acute onset of high spiking fevers, severe rigors, myalgias, retro-orbital headache, and malaise. Rash is rare in anaplasmosis (< 10%), but present in up to 30% of adults and 60% of children with ehrlichiosis (maculopapular or petechial).
• Classic Laboratory Triad: Leukopenia (neutropenia), thrombocytopenia (platelets often < 100 × 10³/μL), and mild-to-moderate transaminitis (AST/ALT elevated 2- to 5-fold).
• Diagnosis: Peripheral blood thin/thick smear examination (demonstrating intracytoplasmic morulae in neutrophils or monocytes; sensitivity 20–60%); definitive confirmation via whole blood PCR.
• Pharmacotherapy:
  • Doxycycline 100 mg PO or IV twice daily for 10 to 14 days is the treatment of choice for all patients, including children of all ages. Clinical defervescence typically occurs within 24 to 48 hours of starting doxycycline.
  • Alternative: Rifampin 300 mg PO BID (used strictly for mild, uncomplicated disease in pregnant patients with severe doxycycline allergies).

3. Babesiosis (Babesia microti)

• Vector & Transmission: Transmitted by Ixodes scapularis nymphal ticks, or via blood transfusion from asymptomatic donors.
• Pathophysiology: Intraerythrocytic protozoan parasite that invades and lyses human red blood cells, causing non-immune microangiopathic hemolytic anemia. Splenic macrophages play a critical role in clearing parasitemic erythrocytes.
• High-Risk Populations for Severe/Lethal Disease: Asplenic patients (anatomical or functional), immunocompromised individuals (SOT, HCT, HIV, rituximab therapy), and patients aged > 65 years. Severe complications include ARDS, severe hemolytic anemia (Hb < 8 g/dL), acute tubular necrosis, DIC, and spontaneous splenic rupture.
• Diagnostic Identification: Peripheral blood smear (Giemsa or Wright stain) demonstrating intraerythrocytic ring forms mimicking Plasmodium falciparum, pathognomonic tetrad configurations ("Maltese cross"), and absence of hemozoin pigment; confirmatory whole blood Babesia PCR.
• Pharmacotherapeutic Management:
  • Mild-to-Moderate Disease:
    • Atovaquone 750 mg PO twice daily PLUS Azithromycin 500 mg PO Day 1, then 250 mg PO once daily for 7 to 10 days.
    • (Clinical trials proved this combination is equally efficacious to clindamycin plus quinine with significantly fewer disabling adverse effects: tinnitus, vertigo, gastrointestinal toxicity).
  • Severe / Life-Threatening Disease:
    • Intravenous Clindamycin 600 mg IV every 6 hours (or 1,200 mg IV q8h) PLUS Oral Quinine 650 mg PO every 8 hours (or IV quinidine with continuous cardiac telemetry monitoring for QTc prolongation).
  • Red Blood Cell Exchange Transfusion (Erythrocytapheresis):
    • Indications: Parasitemia level ≥ 10%, severe unremitting hemolysis with severe anemia (hemoglobin < 8 g/dL), or severe end-organ compromise (pulmonary edema, ARDS, renal failure, or hepatic failure). Exchange transfusion rapidly removes parasitized erythrocytes, clears toxic free hemoglobin, and restores perfusion.

4. Rocky Mountain Spotted Fever (RMSF, Rickettsia rickettsii)

• Vectors & Epidemiology: Transmitted by Dermacentor variabilis (American dog tick), Dermacentor andersoni (Rocky Mountain wood tick), and Rhipicephalus sanguineus (brown dog tick). Endemic throughout North America, with highest incidence in North Carolina, Oklahoma, Arkansas, Tennessee, and Missouri.
• Pathophysiology: Rickettsia rickettsii has a specific tropism for vascular endothelial cells lining small arteries, arterioles, and capillaries. Intracellular replication causes focal endothelial cell necrosis, microvascular leakage, widespread vasculitis, consumption coagulopathy, non-cardiogenic pulmonary edema, cerebritis, and septic shock.
• Clinical Presentation: Abrupt onset of high fever, severe frontal headache, photophobia, profound myalgias, and nausea. The classic rash appears on days 2 to 5 of fever: initial blanching, macular erythematous lesions that begin peripherally on the wrists, ankles, palms, and soles, and spread centripetally toward the trunk. Over subsequent days, lesions become petechial and purpuric.

• Definitive Treatment:
  • Doxycycline 100 mg PO or IV every 12 hours for 7 to 10 days (or for at least 3 days after fever defervescence).
  • Doxycycline is the First-Line Drug of Choice for ALL AGES, Including Children < 8 Years and Pregnant Patients with Severe Suspected RMSF.
  • Pediatric Safety Clarification: Decades of data confirm that short courses of doxycycline (≤ 14 days) do not cause visible tooth staining or enamel hypoplasia in young children. The American Academy of Pediatrics (AAP) and CDC state unequivocally that doxycycline must not be withheld from pediatric patients with suspected RMSF.
  • Pregnancy: Although chloramphenicol has historically been cited for pregnancy, chloramphenicol carries risks of fatal aplastic anemia and gray baby syndrome, has higher mortality and failure rates in RMSF, and is no longer commercially available in the United States. Doxycycline is recommended for life-threatening RMSF regardless of gestational status.